ATP11B

Across TCGA pan-cancer cohorts, ATP11B mass-spec protein is linked to patient survival in 7 of 34 cancer types, making it a survival-associated ATP11B data layer compared with 26 for mass-spec protein and 7 for mutation status.

The strongest signal is observed in clear cell renal cell carcinoma (CCRCC), where higher ATP11B mass-spec protein is associated with worse disease-free survival. In most high-consensus cancer types, elevated ATP11B expression acts as an unfavorable survival marker, although some lineages such as GBM and UCEC show a favorable association.

CCRCC, PDAC, and GBM are the cancer types where ATP11B mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
CCRCC	DFS	Quartile	All	0.534	1.000	<.001	35	view →
PDAC	DFS	Quartile	All	0.695	0.875	.014	8	view →
GBM	DFS	Quartile	All	0.816	0.664	.019	5	view →
OV	DFS	Median	All	0.576	0.882	.025	4	view →
LUAD	DFS	Quartile	II,III,IV	0.352	0.836	.022	4	view →
UCEC	OS	Median	II,III,IV	1.000	0.647	.022	4	view →
LSCC	OS	Tertile	II,III,IV	1.000	0.835	.027	3	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

ATP11B–CCRCC (DFS)

Open the CCRCC breakdown →